Bristol-Myers Squibb and Five Prime Therapeutics have entered an exclusive clinical collaboration to evaluate the safety and efficacy of BMS’ investigational immune checkpoint inhibitor Opdivo (nivolumab) with FPA008, Five Prime’s monoclonal antibody that inhibits colony stimulating factor-1 receptor (CSF1R). The Phase Ia/Ib study will evaluate the combination as a potential treatment for patients with non-small cell lung cancer (NSCLC), melanoma, head and neck cancer, pancreatic cancer, c...